These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19886225)

  • 1. [Changing times for clopidogrel].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2009 Oct; 32(10):361. PubMed ID: 19886225
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
    Alban S
    Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350
    [No Abstract]   [Full Text] [Related]  

  • 3. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
    Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
    J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmazie in unserer Zeit 4/2009].
    Alban S; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344
    [No Abstract]   [Full Text] [Related]  

  • 5. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
    Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
    Agewall S; Cattaneo M; Collet JP; Andreotti F; Lip GY; Verheugt FW; Huber K; Grove EL; Morais J; Husted S; Wassmann S; Rosano G; Atar D; Pathak A; Kjeldsen K; Storey RF;
    Eur Heart J; 2013 Jun; 34(23):1708-13, 1713a-1713b. PubMed ID: 23425521
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug interaction between clopidogrel and proton pump inhibitors.
    Khalique SC; Cheng-Lai A
    Cardiol Rev; 2009; 17(4):198-200. PubMed ID: 19525682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clopidogrel and proton pump inhibitors--boon or bane?].
    Labenz J; Meyners W; Petersen KU
    Dtsch Med Wochenschr; 2010 Feb; 135(5):203-6. PubMed ID: 20104441
    [No Abstract]   [Full Text] [Related]  

  • 9. Clopidogrel and proton pump inhibitor use: what does the evidence really say?
    Baker WL; Coleman CI; Lundbye JB
    Conn Med; 2010 Jan; 74(1):27-31. PubMed ID: 20175370
    [No Abstract]   [Full Text] [Related]  

  • 10. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
    Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
    Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPI interactions with clopidogrel.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):2-3. PubMed ID: 19122567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel (Effient) vs. clopidogrel (Plavix).
    Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clopidogrel plus proton pump inhibitor: is infarct risk increased? (interview by Dr. Thomas Meissner)].
    Petersen KU
    MMW Fortschr Med; 2009 Jun; 151(23):7. PubMed ID: 19591342
    [No Abstract]   [Full Text] [Related]  

  • 14. Clopidogrel and proton pump inhibitors: a clinically meaningful interaction?
    Gerhard T
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):214-8. PubMed ID: 21254294
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clopidogrel. Actions, pharmacokinetics, clinical studies].
    Wunderlich H; Beer J; Allgaier C
    Med Monatsschr Pharm; 2002 Dec; 25(12):425-9. PubMed ID: 12522913
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug regulatory agencies' role in the interaction between clopidogrel and proton pump inhibitors.
    Saiz LC; Alvarez J; Martínez H
    Am J Gastroenterol; 2011 Jul; 106(7):1369-70. PubMed ID: 21731026
    [No Abstract]   [Full Text] [Related]  

  • 17. Prasugrel: a novel platelet ADP P2Y receptor antagonist.
    Wilson W; Gurvitch R; Ajani AE
    Cardiovasc Ther; 2009; 27(3):194-8. PubMed ID: 19689619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that decrease the effectiveness of clopidogrel.
    Aschenbrenner DS
    Am J Nurs; 2009 Jun; 109(6):66-7. PubMed ID: 19478613
    [No Abstract]   [Full Text] [Related]  

  • 19. Can the PFA-100 be modified to detect P2Y12 inhibition?
    Pidcock M; Harrison P
    J Thromb Haemost; 2006 Jun; 4(6):1424-6. PubMed ID: 16706997
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
    Li YG; Ni L; Brandt JT; Small DS; Payne CD; Ernest CS; Rohatagi S; Farid NA; Jakubowski JA; Winters KJ
    Platelets; 2009 Aug; 20(5):316-27. PubMed ID: 19637095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.